RESEARCH: PROTEIN-LIGAND-SIMULATION
FOLDING PROJECT #12276 PROFILE
PROJECT TEAM
Manager(s): Louis SmithInstitution: University of Pennsylvania
WORK UNIT INFO
Atoms: 72,780Core: 0x23
Status: Public
Related Projects
TLDR; PROJECT SUMMARY AI BETA
This project uses computer simulations to study how proteins interact with drugs. They're focusing on a protein called acetylcholinesterase, which is important for nerve function and is targeted by pesticides and some medications. By simulating these interactions, they hope to improve drug discovery methods and develop new treatments.
Note: This TLDR is a simplication and may not be 100% accurate.OFFICAL PROJECT DESCRIPTION
In this series of projects we are simulating proteins that are part of the DUD-E benchmark data set for protein-ligand interactions, using simulations initialized from Alpha Fold. Simulation methods to study protein-small molecule interactions are of critical importance to the early stages of drug discovery, but most methods have a poor balance of accuracy relative to cost.
Much of the development process for new compounds happens via screening large libraries of compounds for activity against target proteins believed to be relevant for a disease.
Lending focus to this search makes developing new molecules into drugs more economical and faster. In order to do this kind of methods development, good reference data that is widely available is essential.
A classic dataset for benchmarking structural methods attempting to predict protein-ligand interactions known as DUD-E has been widely used because it has diverse proteins, and each protein is bound to a fairly large collection (usually more than fifty) of small molecules for which the ability to bind the receptor have been measured experimentally.
Using Folding@Home, we will create large reference quality simulations of these proteins.
Because we know how such simulations, and the binding methods we or others may test on them, should look and function we have a great yardstick for improving the methods we have and developing new ones. In this project series we have the following systems, many of which are known for their medical relevance in addition to having been extensively studied with both simulation and experiment in the past. 12234 - ACES: Acetylcholinesterase that is critical to nervous system function in animals.
It is the target of pesticides, and also numerous drugs.
If targeted in the correct way, it can reduce neural swelling.
This sequence happens to be from the Pacific Electric ray, Torpedo Californica, which was a landmark discovery in biomedical efforts to isolate neurotransmitter receptors and led to a mechanistic understanding of myasthenia gravis. 12235 - AKT2: serine-threonine kinase taking part in the insulin signal transduction pathway.
Implicated in some cancers, it has been a target of drug development campaigns in the past. 12236 - AMPC: A critical antibiotic resistance gene, it is a beta lactamase capable of opening the critical structural feature of celphalosporin-type antibiotics, rendering them ineffective. 12237 - BACE1: Beta secretase 1, an aspartic acid protease that helps form myelin sheaths in neurons.
It is the major generator of amyloid-beta peptides in neurons, and therefore is implicated in Alzheimer's disease. 12238 - BRAF: B-raf is involved in sending signals involved in cell growth, and as such is considered a proto-oncogen.
It is a serine/threonine kinase that has several known inhibitors, some of which are now anti-cancer medications. 12239 - CASP3: a caspase-type protease that participates in the execution of apoptosis, the process of programmed cell death.
It also acts to cleave one of the amyloid forming proteins and is therefore implicated in Alzheimer's dementia. 1240 - CDK2: one of the cyclin dependent kinases, this protein is a checkpoint kinase that signals transitions between growth and DNA synthesis phases in the cell cycle.
Dysfunction in this checkpoint is associated with cancer; inhibiting CDK2 can arrest cell cycle in cases of abmormal growth, so it has been an anti-cancer target for some time. 12241 - CSF1R: Colony stimulating factor 1 receptor, when bound by cognate ligands, will promote survival, proliferation and differentiation of many myeloid cell types.
It is thus involved in disease and is targeted in therapies for cancer, neurodegenerative diseases, nad inflammatory bone diseases. 12242 - DPP4: Dipeptidyl peptidase-4, a protein that cuts up certain other proteins on the surfaces of most cells.
Important in immune regulation, signal transduction, and apoptosis, molecules inhibiting its enzymatic activity can help treat type 2 diabetes because the peptide hormones (GLP-1, and GIP) are degraded by DPP4.
Thus, inhibiting DPP4 prolongs the effects of these hormones. 12243 - EGFR: Epidermal growth factor receptor; its deficient signaling is associated with Alzheimer's dementia, whereas its over-expression is a common characteristic of tumor cells.
It is thus an oncogene that is targeted by numerous anti-cancer molecules and drugs.
Many of these are targeted at the tyrosine kinase domain, because hampering its function prevents excessive transduction of the signals these receptors would otherwise send to the nucleus of the tumor cell. 12244 - ESR1: Estrogen Receptor Alpha is critical to many tissue differentiation processes across the body, and has been targeted by various drugs to both enhance and suppress its effects depending on associated conditions.
12245 - FA10: Coagulation factor X is an enzyme in the coagulation signaling cascade for forming blood clots.
It is a serine endopeptidase, and has been targeted by inhibitors to reduce coagulation in medical contexts where that is desirable.
12246 - FABP4: Fatty Acid Binding protein 4 is a protein that imports lipids between intra and extracellular membranes in macrophages and adipocytes.
Inhibiting it is associated with both preventing certain fat-tumor cancers and metabolic syndromes. 12247 - GRIA2: Glutamate ionotropic receptor AMPA type subunit 2 is a glutamate receptor, an essential neurotransmitter in humans.
Its pre-mRNA is A->I edited at a particular site that makes the channel impermeable to calcium.
Editing errors here can result in ALS, and some other diseases. 12248 - HSP90AA1: Heat shock protein 90kDa alpha A1 is a stress inducible protein that refolds misfolded or damaged proteins.
It is a relevant drug target because it interacts with a number of tumor promoting proteins and plays a large role in cellular adaptation to stress. 12249 - IGF1R: Insulin like growth factor 1 is an extracellular receptor with a tyrosine kinase domain.
It is critical for growth and development, and as such if overproduced can contribute to the cancer phenotype and certain other diseases.
Therefore inhibitors have been developed to target this extracellular receptor. 12250 - ITAL (LFA-1): Leukocyte adhesion cglycoprotein LFA-1 alpha is an integrin found on lymphocytes and other leukocytes.
It functions in the process of tissue emigration in lymphocytes, and in cytotoxic T-cell mediated killing of cells. 12251 - KIT: tyrosine-protein kinase KIT is a receptor tyrosine kinase and a proto-oncogene.
It senses cytokines, transducing signals that govern cell proliferation and survival.
As such it is often mutated in cancers, where its excessive activity maintains or enhances the tumor state. 12252 - MAPK2: Mitogen-activated protein kinase kinase is part of the MAPK pathway, which is famously aberrant in many types of cancers, particularly melanomas.
Inhibitors against it would slow the progression of cancer, so it has been targeted by therapies historically. 12253 - MET: tyrosine-protein kinase Met, also known as hepatocyte growth factor receptor, governs embryonic development, organogenesis and wound-healing.
Abnormal activation of MET sustains tumors by causing them to grow and become better supplied by blood vessels.
Extensive research has focused on inhibiting MET because of its correlation with poor prognosis in cancer, and many compounds are in various parts of the regulatory approval process. 12254 - MK10: MAPK-10 or mitogen-activated protein kinase 10 is associated with a wide variety of cellular processes associated with proliferatiation, differentiation, and development.
Mapk-10 is implicated in neuronal development, and when active can inhibit neuronal apoptosis.
12255 - MK14: MAPK-14 or p38-alpha is another stress and differentiation controlling kinase.
Because of its interaction with inflammatory signaling in the immune system, it is a relevant target for immune diseases and heart disease. 12256 - PPARD: Peroxisome proliferator-activated receptor delta is a nuclear hormone receptor that is implicated in the development of several classes of chronic disease.
Drugs stimulating it can act as biochemical substitutes for exercise, and decouple oxidative phosphorylation.
12257 - PPARG: Peroxisome proliferator activated receptor gamma is similar to the delta variant in some ways, but also serves as a master-regulator of fat cell differentiation.
It has been studied as a target for growth inhibition in cancer cell cultures.
It also is targeted by drugs that treat lipid metabolism disorders like hyperlipidemia and hyperglycemia, as well as for type 2 diabetes as an insulin sensitizer. 12258 - PTN1: Tyrosine-protein phosphatase non-receptor type 1 counteracts the effect of certain tyrosine kinases in protein signalling.
One of its targets is the phosphosite on the insulin receptor and several other receptor tyrosine kinases, including some from this list.
As such, it has implications for both the treatemnt of some cancers and also type 2 diabetes. 12259 - RENI: Renin is an endopeptidase that generates angiotensin 1, resulting in a blood pressure increasing signalling cascade that also causes sodium retention by the kidneys.
As such, renin inhibitors can serve to reduce blood pressure. 12260 - RXRA: Retinoid x receptor alpha is a nuclear receptor that binds retinoic acid, causing transcription of a large number of genes.
12261 - TGFR1: Transforming growth factor beta receptor 1 is a TGF-beta receptor that regulates differentiation in a number of endothelial cell types, and seems to have particular bearing on the development of reproductive tissues.
It has been targeted by studies working to develop cancer therapeutics. 12262 - THRB: Thyroid hormone receptor beta is a nuclear receptor that, when activated by thyroid hormone, initiates a large number of different genes.
Deficiencies in activity can result in thyroid hormone resistance which can cause goiter.
12263 - TRY1: Trypsin-1 is the main form of trypsinogen secreted by the pancreas.
It is an enzyme that breaks down proteins, and defective mutations of it can cause pancreatitis.
It is also a workhorse protein in modern biochemical and biophysical labs. 12264 - TRYB1: Tryptase beta-1 is a trypsin like protease that is secreted as part of Mast-cell activation.
As such it has roles in inflammation associated with asthma, and in cleaving flu's hemagglutinin surface protein (which initiates the experience of flu-like symptoms).
Attempts to produce inhibitors hve so far been difficult, but it has relevance to reducing the severity of the inflammatory response in these conditions. 12265 - VGFR2: Vascular endothelial growth factor receptor number 2 is a tyrosine kinase signaling receptor that binds the vascularization hormone, and causes tissue remodeling to form channels for blood vessel growth.
When over-active or over-expressed this protein supports the vascularization of tumor tissue, making inhibitors targeting it helpful in treating some cancers. 12267 - ABL1: ABL is a protein tyrosine kinase and a prominent proto-oncogen.
Mu
tations in this gene are involved in chronic and acute myelogenous leukemia (A/CML),
and it is the kinase in the fusion protein created by the translocation event that
causes the Philadelphia chromosome, a historically important type of hereditary canc
er risk factor that was visible from analysis of mitotic chromosomes.
Specific treat
ment of these cancers came in part from the development of tyrosine kinase inhibito
rs targeting this protein.
12268 - ANDR: The androgen receptor.
A steroid hormone activated transcription f
actor, it activates a collection of genes that are part of the secondary sex charact
eristics.
Implicated in several varieties of human disease, androgen receptor can no
tably undergo gene duplication events in cancer cells, causing aberrant growth in th
e presence of androgen.
Newer treatments for such cancers involve blocking this rece
ptor.
12270 - FAK1: Focal adhesion kinase.
A protein tyrosine kinase involved in the signaling pathways that cause cells to adhere to one another.
Excess activity is often part of cancer phenomena, and is implicated in metastasis.
It is also cleaved in the 'caspase' cascade resulting in programmed cell death, so this activity is sometimes disrupted in cancers, particularly breast cancers and certain types of ovarian cancers.
A specific class of drugs has emerged to inhibit this molecule as anti-cancer therapies.
12271 - FKBP1: FK506 (tacrolimus) binding protein.
An enzyme that takes part in immune regulation and basic cell processes.
It is the target of immunosuppresive drugs; it may also take part in the dysfunctions in cell signalling associated with some cancers.
Originally discovered as the target of the immunosuppresant tacrolimus used in organ transplants.
12272 - GCR: Glucocorticoid receptor.
Binds cortisol and other glucocorticoid hormones.
Many medications target this receptor because of the changes in gene expression activation or repression of its behavior can induce.
12273 - GLCM: Beta glucocerebrosidase (also called acid beta glucosidase).
An enzyme catalyzing a reaction in glycolipid metabolism; some of its mutants are implicated in parkinsons disease, and Gaucher's disease, a lysozomal storage disease.
12274 - HXK4: Hexokinase IV (glucokinase).
Occurring in the liver and pancreas, and is critical for carbohydrate metabolism in mammals.
An enzyme transcribed in response to insulin signaling, it is relevant for treatment of certain types of diabetes.
Genetic variation can result in genetic diseases similar to diabetes.
12276 - LCK: Lymphocite specific protein tyrosine kinase.
Responsible for the T-cell receptor signalling cascade. 12278 - MCR: Mineralocorticoid receptor.
MR is expressed in many tissues, and does myriad things.
It is activated by aldosterone and glucocorticoids like cortisol.
Targeting MR has relevance for numerous medically relevant biologies, but has been exploited for hypertension/cardiovascular disease.
12279 - PPARA: Peroxisome proliferator-activated receptor.
A receptor activated under conditions of energy deprivation--necessary for ketogenesis, whereby energy is produced from fats while an organism fasts.
12280 - PRGR: Progesterone Receptor.
This receptor binds a key sex hormone having to do with pregnancy and estrous in mammals.
Activating or deactivating this receptor pharmaceutically has been very important for contraceptives and other reproduction-related applications.
12281 - PUR2: GAR transformylase, Phosphoribosylglycinamide formyltransferase.
This enzyme is a critical part of nucleic acid biosynthesis.
Because nucleotides are the building blocks of DNA and RNA, cells that are very metabolically or mitotically active depend on this enzyme more heavily.
As such, this protein is the target of some chemotheraputic treatments.
RELATED TERMS GLOSSARY AI BETA
DUD-E
Directory of Useful Drugs - Experiments
DUD-E is a widely used benchmark dataset for evaluating methods that predict how proteins and small molecules interact. It contains diverse protein structures bound to a large number of small molecules, with experimental binding data available.
Protein-Ligand Interactions
The binding of a protein to a small molecule (ligand).
Protein-ligand interactions are crucial for many biological processes, including drug action. When a drug molecule binds to a specific protein target, it can alter the protein's function and produce a therapeutic effect.
Alpha Fold
A deep learning algorithm for protein structure prediction.
AlphaFold is a groundbreaking AI system that can accurately predict the 3D structure of proteins from their amino acid sequence. This has revolutionized protein research and drug discovery by enabling faster and more efficient design of new drugs.
Drug Discovery
The process of identifying and developing new medications.
Drug discovery is a complex and lengthy process that involves multiple stages, from identifying potential drug targets to clinical trials. It requires expertise in various fields, including biology, chemistry, and pharmacology.
Acetylcholinesterase
An enzyme that breaks down the neurotransmitter acetylcholine.
Acetylcholinesterase (AChE) plays a vital role in nerve impulse transmission by regulating the levels of acetylcholine in synapses. It is a target for many drugs, including pesticides and some medications used to treat Alzheimer's disease.
Pesticides
Chemicals used to kill pests.
Pesticides are widely used in agriculture to protect crops from insects, weeds, and diseases. However, they can also have harmful effects on the environment and human health.
Drugs
Substances used to treat or prevent disease.
Drugs are chemical compounds that have a specific effect on the body. They can be used to treat a wide range of conditions, from infections to chronic diseases.
PROJECT FOLDING PPD AVERAGES BY GPU
Data as of Tuesday, 14 April 2026 06:34:57|
Rank Project |
Model Name Folding@Home Identifier |
Make Brand |
GPU Model |
PPD Average |
Points WU Average |
WUs Day Average |
WU Time Average |
|---|---|---|---|---|---|---|---|
| 1 | GeForce RTX 3090 GA102 [GeForce RTX 3090] |
Nvidia | GA102 | 8,714,231 | 229,773 | 37.93 | 0 hrs 38 mins |
| 2 | GeForce RTX 3090 Ti GA102 [GeForce RTX 3090 Ti] |
Nvidia | GA102 | 7,788,270 | 232,284 | 33.53 | 0 hrs 43 mins |
| 3 | GeForce RTX 3080 Ti GA102 [GeForce RTX 3080 Ti] |
Nvidia | GA102 | 7,783,604 | 229,285 | 33.95 | 0 hrs 42 mins |
| 4 | GeForce RTX 3080 GA102 [GeForce RTX 3080] |
Nvidia | GA102 | 6,863,552 | 220,308 | 31.15 | 0 hrs 46 mins |
| 5 | GeForce RTX 2080 Ti Rev. A TU102 [GeForce RTX 2080 Ti Rev. A] M 13448 |
Nvidia | TU102 | 5,879,915 | 207,870 | 28.29 | 0 hrs 51 mins |
| 6 | GeForce RTX 3080 Lite Hash Rate GA102 [GeForce RTX 3080 Lite Hash Rate] |
Nvidia | GA102 | 5,628,218 | 190,355 | 29.57 | 0 hrs 49 mins |
| 7 | RTX A6000 GA102GL [RTX A6000] |
Nvidia | GA102GL | 5,576,925 | 205,372 | 27.16 | 0 hrs 53 mins |
| 8 | GeForce RTX 2080 Ti TU102 [GeForce RTX 2080 Ti] M 13448 |
Nvidia | TU102 | 5,502,204 | 20,742 | 265.27 | 0 hrs 5 mins |
| 9 | Radeon RX 7900XT/XTX/GRE Navi 31 [Radeon RX 7900XT/XTX/GRE] |
AMD | Navi 31 | 5,118,710 | 126,308 | 40.53 | 0 hrs 36 mins |
| 10 | GeForce RTX 3080 12GB GA102 [GeForce RTX 3080 12GB] |
Nvidia | GA102 | 4,859,726 | 205,557 | 23.64 | 1 hrs 1 mins |
| 11 | GeForce RTX 3070 Ti GA104 [GeForce RTX 3070 Ti] |
Nvidia | GA104 | 4,720,807 | 191,210 | 24.69 | 0 hrs 58 mins |
| 12 | Radeon RX 6900 XT Navi 21 [Radeon RX 6900 XT] |
AMD | Navi 21 | 4,621,811 | 194,355 | 23.78 | 1 hrs 1 mins |
| 13 | TITAN RTX TU102 [TITAN RTX] 16310 |
Nvidia | TU102 | 4,207,317 | 187,221 | 22.47 | 1 hrs 4 mins |
| 14 | GeForce RTX 3070 GA104 [GeForce RTX 3070] |
Nvidia | GA104 | 4,168,374 | 187,136 | 22.27 | 1 hrs 5 mins |
| 15 | GeForce RTX 2080 Super TU104 [GeForce RTX 2080 SUPER] |
Nvidia | TU104 | 4,047,892 | 184,889 | 21.89 | 1 hrs 6 mins |
| 16 | RTX A4500 GA102GL [RTX A4500] |
Nvidia | GA102GL | 3,972,859 | 181,852 | 21.85 | 1 hrs 6 mins |
| 17 | GeForce RTX 4060 AD107 [GeForce RTX 4060] |
Nvidia | AD107 | 3,885,002 | 115,859 | 33.53 | 0 hrs 43 mins |
| 18 | GeForce RTX 3060 Ti GA104 [GeForce RTX 3060 Ti] |
Nvidia | GA104 | 3,838,235 | 182,329 | 21.05 | 1 hrs 8 mins |
| 19 | GeForce RTX 3070 Lite Hash Rate GA104 [GeForce RTX 3070 Lite Hash Rate] |
Nvidia | GA104 | 3,556,671 | 181,303 | 19.62 | 1 hrs 13 mins |
|
|
|||||||
| 20 | GeForce RTX 2080 Rev. A TU104 [GeForce RTX 2080 Rev. A] 10068 |
Nvidia | TU104 | 3,345,583 | 174,415 | 19.18 | 1 hrs 15 mins |
| 21 | GeForce RTX 2080 TU104 [GeForce RTX 2080] |
Nvidia | TU104 | 3,304,785 | 173,994 | 18.99 | 1 hrs 16 mins |
| 22 | Radeon RX 6800/6800XT/6900XT Navi 21 [Radeon RX 6800/6800XT/6900XT] |
AMD | Navi 21 | 3,298,909 | 172,367 | 19.14 | 1 hrs 15 mins |
| 23 | TITAN V GV100 [TITAN V] M 12288 |
Nvidia | GV100 | 3,227,730 | 172,547 | 18.71 | 1 hrs 17 mins |
| 24 | Radeon RX 7700XT/7800XT Navi 32 [Radeon RX 7700XT/7800XT] |
AMD | Navi 32 | 3,227,385 | 58,663 | 55.02 | 0 hrs 26 mins |
| 25 | GeForce RTX 2070 SUPER TU104 [GeForce RTX 2070 SUPER] 8218 |
Nvidia | TU104 | 2,842,020 | 76,272 | 37.26 | 0 hrs 39 mins |
| 26 | Quadro RTX 4000 TU104GL [Quadro RTX 4000] |
Nvidia | TU104GL | 2,840,832 | 165,459 | 17.17 | 1 hrs 24 mins |
| 27 | GeForce RTX 2070 TU106 [GeForce RTX 2070] |
Nvidia | TU106 | 2,806,329 | 164,497 | 17.06 | 1 hrs 24 mins |
| 28 | GeForce RTX 2060 Super TU106 [GeForce RTX 2060 SUPER] |
Nvidia | TU106 | 2,763,693 | 164,327 | 16.82 | 1 hrs 26 mins |
| 29 | GeForce RTX 3060 Ti Lite Hash Rate GA104 [GeForce RTX 3060 Ti Lite Hash Rate] |
Nvidia | GA104 | 2,657,416 | 156,408 | 16.99 | 1 hrs 25 mins |
| 30 | GeForce RTX 3060 Lite Hash Rate GA106 [GeForce RTX 3060 Lite Hash Rate] |
Nvidia | GA106 | 2,595,691 | 129,132 | 20.10 | 1 hrs 12 mins |
| 31 | GeForce RTX 3060 Mobile / Max-Q GA106M [GeForce RTX 3060 Mobile / Max-Q] |
Nvidia | GA106M | 2,569,866 | 160,137 | 16.05 | 1 hrs 30 mins |
| 32 | TITAN Xp GP102 [TITAN Xp] 12150 |
Nvidia | GP102 | 2,421,515 | 156,721 | 15.45 | 1 hrs 33 mins |
| 33 | GeForce RTX 2060 12GB TU106 [GeForce RTX 2060 12GB] |
Nvidia | TU106 | 2,366,515 | 155,987 | 15.17 | 1 hrs 35 mins |
| 34 | GeForce RTX 2060 TU106 [Geforce RTX 2060] |
Nvidia | TU106 | 2,309,290 | 99,447 | 23.22 | 1 hrs 2 mins |
| 35 | GeForce RTX 2070 Mobile TU106BM [GeForce RTX 2070 Mobile] |
Nvidia | TU106BM | 2,293,052 | 153,752 | 14.91 | 1 hrs 37 mins |
| 36 | GeForce RTX 3060 GA106 [GeForce RTX 3060] |
Nvidia | GA106 | 2,281,647 | 152,914 | 14.92 | 1 hrs 37 mins |
| 37 | GeForce RTX 2060 TU104 [GeForce RTX 2060] |
Nvidia | TU104 | 2,184,652 | 146,142 | 14.95 | 1 hrs 36 mins |
| 38 | GeForce RTX 3060 GA104 [GeForce RTX 3060] |
Nvidia | GA104 | 2,016,064 | 146,482 | 13.76 | 1 hrs 45 mins |
| 39 | GeForce GTX 1080 Ti GP102 [GeForce GTX 1080 Ti] 11380 |
Nvidia | GP102 | 2,000,252 | 122,228 | 16.36 | 1 hrs 28 mins |
|
|
|||||||
| 40 | GeForce RTX 2060 Mobile TU106M [GeForce RTX 2060 Mobile] |
Nvidia | TU106M | 1,974,949 | 146,767 | 13.46 | 1 hrs 47 mins |
| 41 | Radeon RX 6700/6700XT/6800M Navi 22 XT-XL [Radeon RX 6700/6700XT/6800M] |
AMD | Navi 22 XT-XL | 1,898,700 | 75,244 | 25.23 | 0 hrs 57 mins |
| 42 | Radeon RX 6600/6600 XT/6600M Navi 23 XT-XL [Radeon RX 6600/6600 XT/6600M] |
AMD | Navi 23 XT-XL | 1,837,821 | 143,203 | 12.83 | 1 hrs 52 mins |
| 43 | GeForce RTX 2070 Mobile TU106M [GeForce RTX 2070 Mobile] |
Nvidia | TU106M | 1,807,966 | 142,099 | 12.72 | 1 hrs 53 mins |
| 44 | RTX A2000 GA106 [RTX A2000] |
Nvidia | GA106 | 1,713,239 | 139,637 | 12.27 | 1 hrs 57 mins |
| 45 | GeForce GTX 1660 SUPER TU116 [GeForce GTX 1660 SUPER] |
Nvidia | TU116 | 1,681,409 | 81,284 | 20.69 | 1 hrs 10 mins |
| 46 | GeForce GTX 1080 GP104 [GeForce GTX 1080] 8873 |
Nvidia | GP104 | 1,671,512 | 84,636 | 19.75 | 1 hrs 13 mins |
| 47 | GeForce GTX 980 Ti GM200 [GeForce GTX 980 Ti] 5632 |
Nvidia | GM200 | 1,654,561 | 138,670 | 11.93 | 2 hrs 1 mins |
| 48 | Radeon RX 7700S/7600(S) Navi 33 [Radeon RX 7700S/7600(S)] |
AMD | Navi 33 | 1,599,828 | 136,801 | 11.69 | 2 hrs 3 mins |
| 49 | Geforce RTX 3050 GA106 [Geforce RTX 3050] |
Nvidia | GA106 | 1,572,204 | 136,233 | 11.54 | 2 hrs 5 mins |
| 50 | GeForce GTX 1070 GP104 [GeForce GTX 1070] 6463 |
Nvidia | GP104 | 1,553,214 | 110,205 | 14.09 | 1 hrs 42 mins |
| 51 | RTX A2000 12GB GA106 [RTX A2000 12GB] |
Nvidia | GA106 | 1,537,798 | 134,379 | 11.44 | 2 hrs 6 mins |
| 52 | GeForce RTX 3050 Ti Mobile GA107M [GeForce RTX 3050 Ti Mobile] |
Nvidia | GA107M | 1,498,045 | 134,049 | 11.18 | 2 hrs 9 mins |
| 53 | GeForce GTX 1060 6GB GP106 [GeForce GTX 1060 6GB] 4372 |
Nvidia | GP106 | 1,036,800 | 20,742 | 49.99 | 0 hrs 29 mins |
| 54 | GeForce GTX 980 GM204 [GeForce GTX 980] 4612 |
Nvidia | GM204 | 973,786 | 116,008 | 8.39 | 2 hrs 52 mins |
| 55 | GeForce GTX 1060 3GB GP106 [GeForce GTX 1060 3GB] 3935 |
Nvidia | GP106 | 641,091 | 66,882 | 9.59 | 2 hrs 30 mins |
| 56 | Quadro T1000 Mobile TU117GLM [Quadro T1000 Mobile] |
Nvidia | TU117GLM | 552,813 | 98,447 | 5.62 | 4 hrs 16 mins |
| 57 | GeForce GTX 1650 Ti Mobile TU117M [GeForce GTX 1650 Ti Mobile] |
Nvidia | TU117M | 487,049 | 92,451 | 5.27 | 4 hrs 33 mins |
| 58 | GeForce GTX 1050 Ti GP107 [GeForce GTX 1050 Ti] 2138 |
Nvidia | GP107 | 441,741 | 92,989 | 4.75 | 5 hrs 3 mins |
| 59 | GeForce GTX 1050 LP GP107 [GeForce GTX 1050 LP] 1862 |
Nvidia | GP107 | 432,000 | 20,742 | 20.83 | 1 hrs 9 mins |
|
|
|||||||
| 60 | GeForce GTX 950 GM206 [GeForce GTX 950] 1572 |
Nvidia | GM206 | 311,938 | 79,194 | 3.94 | 6 hrs 6 mins |
| 61 | GeForce MX150 GP107M [GeForce MX150] |
Nvidia | GP107M | 165,526 | 64,379 | 2.57 | 9 hrs 20 mins |
| 62 | GeForce GT 1030 GP108 [GeForce GT 1030] |
Nvidia | GP108 | 86,400 | 20,742 | 4.17 | 5 hrs 46 mins |
PROJECT FOLDING PPD AVERAGES BY CPU BETA
Data as of Tuesday, 14 April 2026 06:34:57|
Rank Project |
CPU Model |
Logical Processors (LP) |
PPD-PLP AVG PPD per 1 LP |
ALL LP-PPD (Estimated) |
Make |
|---|